The journey of reaching low disease activity (LDA) or remission is unique to each individual patient because RA is a complicated disease. Yet, about 90% of RA patients who fail a DMARD like methotrexate are prescribed an anti-TNF biologic therapy, even though only about one in three RA patients will reach LDA or remission on these drugs. Those who do not respond to these drugs are exposed to potentially dangerous side effects and disease progression while wasting money on ineffective prescription costs.
It’s time to stop treating all RA patients the same and create a treatment road map unique to them.
A simple blood test to Predict Non-Response to Anti-TNF Therapies for Patients with RA
Currently, there is no tool to predict which patient will respond to which treatment today, so patients are being treated uniformly rather than based on their unique disease biology.
The need for a test to help rheumatologists avoid prescribing anti-TNF therapy to patients who will not respond, allowing these patients to start alternative approved targeted therapies earlier to help reach LDA is clear. PrismRA is a blood test being developed to meet such a need and is now ready to be studied in the clinic.
Determine the predictive ability of PrismRA to identify anti-TNF therapy non-responders in female and/or all rheumatoid arthritis patients with moderate or high disease activity using standard clinical outcome measures